, Volume 35, Issue 3, pp 140–146

Diabetes und Herzinsuffizienz

  • Christian A. Schneider
  • Roman Pfister
  • Erland Erdmann


Die Herzinsuffizienz ist eine häufige Komplikation des Typ-2-Diabetes und mit einer schlechten Prognose vergesellschaftet. Wie für herzinsuffiziente Patienten ohne Diabetes mellitus gelten alle diagnostischen und therapeutischen Prinzipien in gleicher Weise; diabetesspezifische prospektive Studien fehlen bislang allerdings. Der optimale HbA1c-Zielwert für diese Patientengruppe ist genauso unbekannt wie die optimale blutzuckersenkende Therapie. In Ermangelung prospektiv- randomisierter Studien muss sich die Behandlung deshalb an allgemeinen Therapieprinzipien (Nebenwirkungsarmut, Kombinationstherapie, patientenfreundliche Dosierung, Kosten) orientieren.


Diabetes Herzinsuffizienz Diagnostik NT-proBNP ACE-Hemmer β-Blocker Insulin Glitazon 

Diabetes and Heart Failure


Heart failure is a common complication of type 2 diabetes and bears a poor prognosis. For patients with diabetes and heart failure the commonly accepted standards for diagnosis and treatment of heart failure are to be applied, although prospective diabetes- specific trials are lacking. The optimum HbA1c target value as well as the optimum blood glucoselowering treatment are not known. Due to an absence of prospective randomized trials the treatment should follow general therapeutic principles (low incidence of side effects, combination therapy, patient-friendly dosage, costs).

Key Words:

Diabetes Heart failure Diagnosis NT-proBNP ACE inhibitors β-blockers Insulin Glitazones 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Zhou L, Deng W, Zhou L, et al. Prevalence, incidence and risk factors of chronic heart failure in the type 2 diabetic population: systematic review. Curr Diabetes Rev 2009;5:171–84.CrossRefPubMedGoogle Scholar
  2. 2.
    From AM, Leibson CL, Bursi F, et al. Diabetes in heart failure: prevalence and impact on outcome in the population. Am J Med 2006;119:591–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Yancy CW, Lopatin M, Stevenson LW, et al. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) database. J Am Coll Cardiol 2006;47:76–84.CrossRefPubMedGoogle Scholar
  4. 4.
    Kalogeropoulos A, Georgiopoulou V, Harris TB, et al. Glycaemic status and incident heart failure in elderly without history of diabetes mellitus: the health, aging, and body composition. J Card Fail 2009;15:593–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Leung AA, Eurich DT, Lamb DA, et al. Risk of heart failure in patients with recent-onset type 2 diabetes: population-based cohort study. J Card Fail 2009;15:152–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Bertoni AG, Hundley WG, Massing MW, et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004;27:699–703.CrossRefPubMedGoogle Scholar
  7. 7.
    Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974;34:29–34.CrossRefPubMedGoogle Scholar
  8. 8.
    Ingelsson E, Sundstrom J, Arnlov J, et al. Insulin resistance and risk of congestive heart failure. JAMA 2005;294:334–41.CrossRefPubMedGoogle Scholar
  9. 9.
    Ingelsson E, Arnlov J, Lind L, et al. Metabolic syndrome and risk for heart failure in middle-aged men. Heart 2006;92:1409–13.CrossRefPubMedGoogle Scholar
  10. 10.
    Held C, Gerstein HC, Yusuf S, et al. Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation 2007;115:1371–5.CrossRefPubMedGoogle Scholar
  11. 11.
    Wang J, Sarnola K, Ruotsalainen S et al. The metabolic syndrome predicts incident congestive heart failure: a 20-year follow-up study of elderly Finns. Atherosclerosis:in press (Epub 2009 Nov 10).Google Scholar
  12. 12.
    Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405–12.CrossRefPubMedGoogle Scholar
  13. 13.
    Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001;103:2668–73.PubMedGoogle Scholar
  14. 14.
    Nichols GA, Hillier TA, Erbey JR, et al. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 2001;24:1614–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Suskin N, McKelvie RS, Burns RJ, et al. Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur Heart J 2000;21:1368–75.CrossRefPubMedGoogle Scholar
  16. 16.
    Swan JW, Anker SD, Walton C, et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol 1997;30:527–32.CrossRefPubMedGoogle Scholar
  17. 17.
    Amato L, Paolisso G, Cacciatore F, et al. Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group. Diabetes Metab 1997;23:213–8.PubMedGoogle Scholar
  18. 18.
    Ashgar O, Al-Sunni A, Khavandi K et al. Diabetic cardiomyopathy. Clin Sci (Lond) 2009;116:741–60.CrossRefGoogle Scholar
  19. 19.
    O’Donoghue M, Kenney P, Oestreicher E, et al. Usefulness of aminoterminal pro-brain natriuretic peptide testing for the diagnostic and prognostic evaluation of dyspneic patients with diabetes mellitus seen in the emergency department (from the PRIDE study). Am J Cardiol 2007;100:1336–40.CrossRefPubMedGoogle Scholar
  20. 20.
    McDonald MR, Petrie MC, Varyani F, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2008;29:1377–85.CrossRefGoogle Scholar
  21. 21.
    Kamalesh M, Cleophas TJ. Heart failure due to systolic dysfunction and mortality in diabetes: pooled analysis of 39505 subjects. J Card Fail 2009;15:305–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Cohn JN. The prevention of heart failure — a new agenda. N Engl J Med 1992;327:725–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Ryden L, Armstrong PW, Cleland JG, et al. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J 2000;21:1967–78.CrossRefPubMedGoogle Scholar
  24. 24.
    Shindler DM, Kostis JB, Yusuf S, et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies Of Left Ventricular Dysfunction (SOLVD) trials and registry. Am J Cardiol 1996;77:1017–20.CrossRefPubMedGoogle Scholar
  25. 25.
    Zannad F, Briancon S, Juilliere Y, et al. Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL study. Épidémiologie de l’Insuffisance Cardiaque Avancée en Lorraine. J Am Coll Cardiol 1999;33:734–42.CrossRefPubMedGoogle Scholar
  26. 26.
    Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003;41:1529–38.CrossRefPubMedGoogle Scholar
  27. 27.
    Deedwania PC, Giles TD, Klibaner M, et al. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J 2005;149:159–67.CrossRefPubMedGoogle Scholar
  28. 28.
    Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309–21.CrossRefPubMedGoogle Scholar
  29. 29.
    Hoppe UC, Freemantle N, Cleland JG, et al. Effect of cardiac resynchronization on morbidity and mortality of diabetic patients with severe heart failure. Diabetes Care 2007;30:722–4.CrossRefPubMedGoogle Scholar
  30. 32.
    Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart OutcomesPrevention Evaluation Study Investigators. N Engl J Med 2000;342:145–53.CrossRefPubMedGoogle Scholar
  31. 33.
    Carr AA, Kowey PR, Devereux RB, et al. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. Am J Cardiol 2005;96:1530–6.CrossRefPubMedGoogle Scholar
  32. 34.
    The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560–72.CrossRefGoogle Scholar
  33. 35.
    Eshaghian S, Horwich TB, Fonarow GC. An unexpected inverse relationship between HbA1c levels and mortality in patients with diabetes and advanced systolic heart failure. Am Heart J 2006;151:91.e1–6.CrossRefGoogle Scholar
  34. 36.
    Aguilar D, Bozkurt B, Ramasubbu K et al. Relationship of haemoglobin A1C and mortality in heart failure with diabetes. J Am Coll Cardiol 2009;54:422–8.CrossRefPubMedGoogle Scholar
  35. 37.
    Eurich DT, Tsuyuki RT, Majumdar SR et al. Metformin treatment in diabetes and heart failure: when academic equipoise meets clinical reality. Trials 2009;10:1–7.CrossRefGoogle Scholar
  36. 38.
    Masoudi FA, Inzucchi SE, Wang Y, et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005;111:583–90.CrossRefPubMedGoogle Scholar
  37. 39.
    Eurich DT, McAlister FA, Blackburn DF, et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 2007;335:497.CrossRefPubMedGoogle Scholar
  38. 40.
    Inzucchi SE, Masoudi FA, Wang Y, et al. Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project. Diabetes Care 2005;28:1680–9.CrossRefPubMedGoogle Scholar
  39. 41.
    Shah DD, Fonarrow GC, Horwich T Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes. J Card Fail 2010;16:200–6.CrossRefPubMedGoogle Scholar
  40. 42.
    McAlister FA, Eurich DT, Majumdar SR, et al. The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. Eur J Heart Fail 2008;10:703–8.CrossRefPubMedGoogle Scholar
  41. 43.
    Tzoulaki I, Molokhia M, Curcin V, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009;339:B4731.CrossRefPubMedGoogle Scholar
  42. 44.
    Delea TE, Edelsberg JS, Hagiwara M, et al. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care 2003;26:2983–9.CrossRefPubMedGoogle Scholar
  43. 45.
    Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007;370:1129–36.CrossRefPubMedGoogle Scholar
  44. 46.
    The BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009;360:2503–15.CrossRefGoogle Scholar
  45. 47.
    Erdmann E, Charbonnel B, Wilcox RG, et al. Pioglitazone use and heart failure in patients with type 2 diabetes and pre existing cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 2007;30:2773–8.CrossRefPubMedGoogle Scholar
  46. 48.
    Dargie HJ, Hildebrandt PR, Riegger GA, et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart failure. J Am Coll Cardiol 2007;49:1696–704.CrossRefPubMedGoogle Scholar
  47. 49.
    Giles TD, Miller AB, Elkayam U, et al. Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic function. J Card Fail 2008;14:445–52.CrossRefPubMedGoogle Scholar
  48. 50.
    Murcia AM, Hennekens CH, Lamas GA, et al. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. Arch Intern Med 2004;164:2273–9.CrossRefPubMedGoogle Scholar
  49. 51.
    Pocock SJ, Wang D, Pfeffer MA, et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 2006;27:65–75.CrossRefPubMedGoogle Scholar
  50. 52.
    Karter AJ, Ahmed AT, Liu J, et al. Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet Med 2005;22:986–93.CrossRefPubMedGoogle Scholar
  51. 53.
    Poornima I, Brown SB, Bhashyam S. Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circ Heart Fail 2008;1:153–60.CrossRefPubMedGoogle Scholar
  52. 54.
    Nikolaidis LA, Elahi D, Hentosz T, et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004;110:955–61.CrossRefPubMedGoogle Scholar
  53. 55.
    Sokos GG, Nikolaidis LA, Mankad S, et al. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006;12:694–9.CrossRefPubMedGoogle Scholar
  54. 56.
    Noyan-Ashraf MH, Momen MA, Ban K, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009;58:975–83.CrossRefPubMedGoogle Scholar
  55. 57.
    Timmers L, Henriques JP, de Kleijn DP, et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 2009;53:501–10.CrossRefPubMedGoogle Scholar
  56. 58.
    Wolf R, Frederich R, Fiedorek F, et al. Evaluation of CV risk in the saxagliptin clinical trials. Presented at the 69th Annual Scientific Sessions of the American Diabetes Association, New Orleans, LA, June 5–9, 2009:abstract LB-8.Google Scholar

Copyright information

© Urban & Vogel, Muenchen 2010

Authors and Affiliations

  • Christian A. Schneider
    • 1
    • 2
  • Roman Pfister
    • 1
  • Erland Erdmann
    • 1
  1. 1.Klinik III für Innere Medizin, HerzzentrumUniversität zu KölnKölnGermany
  2. 2.Klinik III für Innere Medizin, HerzzentrumUniversität zu KölnKölnGermany

Personalised recommendations